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The potential of repetitive transcranial magnetic stimulation (rTMS) to treat numerous 
neurological and psychiatric disorders has been thoroughly studied for the last two 
decades. Here, we report for the first time, the case of a 65-year-old woman suffering from 
treatment-resistant depression who developed an acute frontal lobe syndrome following 
eight sessions of low-frequency rTMS (LF-rTMS) to the right dorsolateral prefrontal cortex 
while also treated with sertraline and mianserin. The pathophysiological mechanisms 
underlying such an unexpected acute frontal lobe dysfunction are discussed in relation 
to the therapeutic use of LF-rTMS in combination with pharmacotherapy in depressed 
patients.
Keywords: depression, transcranial magnetic stimulation, frontal syndrome, antidepressant, state-dependency, 
executive dysfunction
BaCKGRoUND
Over the past two decades, repetitive transcranial magnetic stimulation (rTMS) has shown promise 
in the treatment of a myriad of neurological and psychiatric conditions such as Parkinson’s disease, 
neuropathic pain, stroke, depression, and auditory hallucinations (1, 2). rTMS involves the use of 
a magnetic field to induce an electric current in cortical regions, in order to modulate their activity 
levels and those of their associated networks. Different stimulation parameters are combined in 
order to induce lasting increases or decreases of neuronal activity. rTMS was approved in 2008 by 
the Food and Drug Administration as a treatment for major depressive disorder (MDD) in patients 
who did not respond to at least one antidepressant medication (1–3). In a recent meta-analysis of 
MDD and treatment-resistant depression [TRD (4)], the administration of low-frequency rTMS 
(LF-rTMS) to the right dorsolateral prefrontal cortex (rDLPFC) proved efficacy in 30–40% of 
patients. Despite some rare adverse effects [including seizures, local pain, transient hypomanic or 
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manic episode, and delusion (1, 5–8)], rTMS is then considered a 
well-tolerated method to treat depression. Herein, we report the 
first case of acute frontal lobe dysfunction induced by a concur-
rent administration of LF-rTMS and antidepressant treatment in 
a TRD patient. Neuropsychological and neuroimagery investiga-
tions revealed a temporal association between transient clinical 
symptoms and reversible brain alterations. We further discuss the 
pathophysiological hypothesis of such acute frontal lobe dysfunc-
tion, and the specificity of the delivery of rTMS concurrently with 
the administration of psychotropic medication. Our patient gave 
written consent to publish this case report.
Case pReseNtatIoN
History and symptoms at presentation
A 65-year-old right-handed retired woman presented with a 
depressive relapse. Her medical history revealed hypertension, 
hyperlipidemia, and rheumatoid arthritis in clinical remission for 
6 years (DAS 28 score: 1.74), treated weekly with methotrexate 
[15 mg once daily (od)]. She reported neither a history of addic-
tive behavior nor any neurological medical condition. She suf-
fered from a TRD of 25 years (recurrent resistant episodes, with 
resistance to several types of antidepressant treatment, including 
resistance to electroconvulsive therapy), without any event of 
suicidal behavior or hypomanic/manic episode. She was treated 
with fluoxetine (40 mg od) and clomipramine (75 mg od) before 
relapsing. At presentation, she reported sadness, loss of interest, 
psychomotor retardation, thoughts of worthlessness, hyporexia, 
and difficulty concentrating. No agitation, irritability, insomnia, 
confusional state, or suicidal thoughts were reported. She was 
diagnosed with a severe TRD according to the Diagnostic and 
Statistical Manual of Mental Disorders IV-TR.
Clinical Course and Management
Considering her TRD and clomipramine-induced orthostatic 
hypotension, treatment was progressively switched to mianserin, 
sertraline, and diazepam. LF-rTMS was initiated 2 weeks after the 
onset of the new pharmacological treatment [at an intermediary 
dosage, mianserin (10 mg od), sertraline (50 mg od), and diaz-
epam (2 mg od)], over the rDLPFC [Magstim Rapid2 stimulator 
(Whitland, UK, www.magstim.com), using a 70-mm diameter 
figure-of-eight coil, at 110% of resting motor threshold, with 
continuous patterns at 1 Hz (1,000 pulses/day) which followed 
international guidelines for clinical rTMS uses (1)].
The cortical target was defined as the scalp location 6  cm 
rostral and in a parasagittal plane from the hotspot of the abduc-
tor pollicis brevis muscle in the primary motor cortex (M1). 
Pretreatment assessments including standard blood tests, brain 
computerized tomography scanner, and electroencephalography 
(EEG) were normal.
After the eighth rTMS session, the patient presented signifi-
cant behavioral changes, including disinhibition, loss of manners, 
decrease in personal grooming, perseverative behaviors, hypero-
rality with sweet cravings, and impulsive actions (the patient ran 
away from the hospital to buy large amounts of chocolate at the 
supermarket). Aspontaneity and economy of speech without 
aphasia were also observed. She did not exhibit elevated mood, 
tachypsychia, logorrhea, or insomnia, excluding a diagnosis of 
hypomanic/manic episode. Moreover, the patient did not report 
any delusion or hallucination. On a neurological evaluation, the 
patient was alert and oriented, without any motor or sensitive 
deficit. However, the patient exhibited signs of right frontal lobe 
dysfunction including distractibility, environmental dependency, 
and left-sided visuospatial neglect (9).
Considering this acute frontal syndrome, we conducted an 
extensive checkup in order to rule out any acute neurological 
etiology. Epilepsy was ruled out with an EEG conducted during 
the acute symptomatic phase, revealing no ictal activity, nota-
bly in the frontal and temporal areas (even after provocation 
with hyperventilation test and flicker-fusion test). A second 
control EEG was conducted 7 days after the first EEG, reveal-
ing no abnormalities. Viral and bacterial encephalitis were 
ruled out by normal blood tests and cerebral spinal fluid (CSF) 
analysis [normal cell counts including no pleocytosis (0 cells), 
normal CSF protein level (0.33 g/L), normal CSF glucose level 
(3.5 mmol/L), negative HSV1/2-PCR, negative 14-3-3 protein]. 
General metabolic disturbances were ruled out by normal 
laboratory tests (normal glycemia, calcemia, and natremia). In 
order to rule out the hypothesis of an acute ischemic stroke, a 
1.5 T brain magnetic resonance imaging (MRI) was performed 
on day 1. Right DLPFC hyperintensity on diffusion-weighted 
imaging was reported with a significant decreased apparent dif-
fusion coefficient (ADC) as compared to the homotopic region 
[difference of 0.039 × 10−3 mm2/s, showing 0.723 in the rDLPFC 
versus 0.762 in the left DLPFC (×10−3 mm2/s), see Figure 1]. 
Nonetheless, these findings lacked an association with a high 
signal in FLAIR sequence more than 24  h after the onset of 
symptoms, and ADC level in our patient was higher than ADC 
level seen in patients suffering from an acute ischemic stroke 
(ADC mean in acute ischemic stroke =  0.533 ×  10−3  mm2/s, 
SD = 0.157, 95% confidence intervals: 0.501–0.563) (10). The 
hypothesis of an acute ischemic stroke was then ruled out. In 
the context of rheumatoid arthritis, it was important to rule 
out the hypothesis of a cerebral vasculitis. First, considering 
rheumatoid arthritis, our patient had been in clinical remission 
for 6 years. There was no systemic sign of inflammatory activ-
ity, on a clinical and paraclinical level (including fever, fatigue, 
arthralgia, edema, cardiopulmonary function, renal and hepatic 
function, peripheral neuropathy, ophthalmic abnormalities). 
Second, blood tests were unremarkable {no inflammatory 
syndrome [normal C-reactive protein, normal white blood cell 
count, normal albuminemia (38  g/L)], normal serum protein 
electrophoresis}, and there was no inflammatory process 
revealed by CSF analysis (as already described). Furthermore, 
ADC level was not consistent with ADC level seen in acute 
ischemic stroke of any kind, including acute stroke induced by 
cerebral vasculitis (10). As the patient was treated with metho-
trexate, we aimed to address its imputability in the occurrence 
of such acute frontal syndrome. Methotrexate intake has always 
been well tolerated in our patient for 6 years. Our patient did 
not show any hypersensitivity reaction to methotrexate. She was 
supplemented with B vitamins, and laboratory tests revealed no 
vitamin deficiency. Finally, the period of time between the last 
FIGURe 1 | (a) 1.5 T brain magnetic resonance imaging (MRI) performed on day 1 showing a right dorsolateral prefrontal cortex (rDLPFC) hyperintensity on 
diffusion-weighted imaging with a significant decreased apparent diffusion coefficient (ADC) as compared to the homotopic region in the left hemisphere [difference 
of 0.039 × 10−3 mm2/s, showing 0.723 in the rDLPFC versus 0.762 in the left DLPFC (×10−3 mm2/s)]; (B) control brain MRI performed on day 9 after the onset of 
symptoms using the same MRI scanner and identical acquisition parameters revealing normal ADC levels on both DLPFC areas [no significant difference, showing 
0.803 in the rDLPFC versus 0.785 in the left DLPFC (×10−3 mm2/s)].
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intake of methotrexate and the acute phase had to be taken into 
account. Nonetheless, the reversibility of frontal symptoms was 
not correlated with a modification of this specific treatment. All 
put together, there was no argument in favor of a methotrexate-
induced encephalitis.
After having ruled out these hypotheses, we tried to specify 
the frontal lobe dysfunction by conducting a neuropsycho-
logical evaluation in combination with other brain imaging 
techniques. Neuropsychological evaluation revealed deficits 
in executive and working memory tasks, without any instru-
mental impairment (see Table S1 in Supplementary Material). 
A brain 99mTc-hexamethylpropyleneamine oxime single-
photon emission computerized tomography (99mTc-HMPAO 
SPECT) performed 13  days after the onset of symptoms 
revealed a significant decrease in regional cerebral blood flow 
(rCBF) within the rDLPFC (see Figure 2).
Repetitive TMS and sertraline were discontinued and the 
patient’s frontal lobe syndrome started to decline after 10 days off 
treatment. A control MRI performed on day 9 showed normal 
ADC levels in the rDLPFC [no significant difference, showing 
0.803 in the rDLPFC versus 0.785 in the left DLPFC (×10−3 mm2/s), 
see Figure 1]. At the 3-month follow-up examination, the patient 
was stabilized on a regimen of mianserin 30 mg od in a complete 
recovery state, with a regression of the frontal dysfunction and a 
normalization of all neuropsychological functions. A 10-month 
control 99mTc-HMPAO SPECT revealed a complete cancelation 
of the rDLPFC rCBF decrease (see Figure 2).
DIsCUssIoN
Safety and potential side effects of LF-rTMS have been moni-
tored clinically in thousands of depression patients and healthy 
controls to date (1, 2). Occasionally, studies have reported mild 
cognitive changes associated with the use of rTMS (improvement 
in number processing, memory recall, and creativity, or excessive 
tiredness, difficulty concentrating, and memory impairment), 
but these rare effects were subtle and lasted no more than several 
minutes (11–13). The current case report highlights the potential 
induction of an acute frontal lobe syndrome lasting up to a week, 
on a regime of LF-rTMS/antidepressant association.
We first placed particular emphasis on differential diagnosis. 
Psychiatric evaluation ruled out hypomania and mania, as 
described above. Moreover, the incidence of treatment-emergent 
mania is very low with rTMS and remains controversial (7). 
Nevertheless, we cannot exclude similar rTMS-induced cogni-
tive dysfunctions as the one observed in our patient might have 
passed unnoticed. Indeed, some of the side effects of rTMS, such 
as agitation, hypomania, or mixed depressive episode, share 
core symptoms with a frontal lobe syndrome, and thus could 
easily be misdiagnosed (7, 8, 14, 15). Interestingly, all neurologic 
symptoms observed resolved shortly after the discontinuation of 
LF-rTMS and sertraline, without the use of specific therapeutics 
such as mood stabilizers.
Given the previous antidepressant switch in our patient, the 
risk for an antidepressant discontinuation syndrome (ADS) 
also needs to be considered. However, considering the 2-week 
latency between the antidepressant switch and the occurrence of 
symptoms, this possibility seems unlikely. Moreover, transient 
frontal lobe syndrome has never been reported in the context of 
an ADS (16).
Finally, as described above, behavioral changes, dysexecutive 
syndrome, and left-sided visual neglect exhibited by the patient 
strongly suggest a focal dysfunction associated with rDLPFC 
(9, 17). Remarkably, brain MRI and 99mTc-HMPAO SPECT 
revealed, respectively, transient diffusion and rDLPFC rCBF 
abnormalities overlapping with the area of LF-rTMS stimulation. 
FIGURe 2 | (a) Brain 99mTc-hexamethylpropyleneamine oxime single-photon emission computerized tomography (99mTc-HMPAO SPECT) performed 13 days 
after the onset of symptoms revealing a significant decrease in regional cerebral blood flow (rCBF) within the right dorsolateral prefrontal cortex (see white arrows); 
(B) a 10-month control 99mTc-HMPAO SPECT showing a complete cancelation of the right frontal rCBF decrease present during the symptoms.
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These results raise the question of the correlation between 
clinical and abnormal imaging findings reported above. Previous 
TMS studies have also found a decrease in rDLPFC rCBF after 
LF-rTMS (18), and even a correlation between rDLPFC rCBF 
decreases and the efficacy of LF-rTMS (19). In addition, some 
studies outlined how LF-rTMS has the ability to modulate rCBF 
and brain diffusion and that such effects might scale with the 
clinical outcome (20, 21).
Considering the clinical presentation, what remains unclear 
here is the mechanism linking the LF-TMS-antidepressant 
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treatment association to such acute behavioral degradation. 
SSRIs are preferentially known to induce indifference and apa-
thy (22). Though, medication might have interfered with rTMS 
treatment. Mianserin and sertraline, alone or in combination, 
form a relative hazard for application of rTMS due to their sig-
nificant seizure threshold lowering potential (1). Furthermore, 
recent research has demonstrated the strong state-dependency 
of the rTMS effects (23). The magnitude and even the net sign 
of the stimulation may depend on the state of activity of the 
targeted area. Thus, a brain region kept in a high state of activity 
may be more responsive to rTMS-mediated suppression than 
one with either normal or suppressed levels of activity (23). We 
therefore suggest that rTMS inhibitory effect might have been 
strongly potentiated through pharmacological preconditioning 
in our patient, lowering the excitability threshold of the rDLPFC 
and its associated network, hence inducing a transient change 
in the functioning of this neuronal network. Such widespread 
effect induced from a focal stimulation has been well described 
in animals and humans with positron emission tomography 
studies (24).
CoNCLUDING ReMaRKs
Repetitive transcranial magnetic stimulation/antidepressant treat- 
ment association is a very promising approach in the treatment of 
TRD. However, little is known on the neurophysiological mecha-
nisms involved in such potentiation. To our knowledge, this is the 
first report of an acute frontal dysexecutive syndrome potentially 
mediated by rTMS/antidepressant treatment association in a 
TRD patient. Nonetheless, this report has to be considered with 
caution as this phenomenon occurred in a single case. Further 
rTMS/antidepressant studies are needed to explore such interac-
tion and the mechanisms encountered in our patient. Moreover, 
our clinical observation provides support to adequately titrate 
rTMS/antidepressant treatment associations to boost the effects 
of rTMS for the therapy of TRD.
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